Neisseria meningitidis consists of 13 serogroups that cause meningococcal disease. The serogroups A, B, C, W, X, and Y cause the most disease worldwide and the serogroups B, C, and Y cause the most disease in the United States. FDA researchers have isolated multiple strains of neisseria meningitidis as potential candidates for vaccine development including the X serotype.
- Neisseria meningitidis X strain M8210 (E-2013-017)
- Neisseria meningitidis Y strain S1975 (E-2013-018)
- Neisseria meningitidis A strain M1027 (E-2013-019)
- Neisseria meningitidis C strain C11 (E-2013-020)
- Neisseria meningitidis W-135 strain S877 (E-2013-021)
|Potential Commercial Applications||Competitive Advantages|
Development Stage: Research Materials
Inventors: Willie Vann, Che-Hung Lee
- Muindi, KM., et. al. Characterization of the meningococcal serogroup X capsule N-acetylglucosamine-1-phosphotransferase. Glycobiology. 2014 Feb;24(2):139-49. PMID: 24134880
- Gudlavalleti, SK., et. al. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide. Vaccine. 2007 Nov 14;25(46):7972-80.PMID: 17936445
Product Area: Research materials, vaccine, diagnostic
FDA Reference No: E-2013-017, E-2013-018, E-2013-019, E-2013-020, E-2013-021
Ken Miliburne, J.D.
FDA Technology Transfer Program